TARCEVA 150 mg, film-coated tablet 30 tablets
Active ingredients: Erlotinib, Erlotinib hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TARCEVA 150 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- CHEPLAPHARM REGISTRATION (ALLEMAGNE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Nov 2005
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63390528CIP73692352CIP133400936923522Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ERLOTINIB (CHLORHYDRATE D')comprimé | — | SA |
| ERLOTINIBcomprimé | 150 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.